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In this month’s issue of the Netherlands Heart Journal,
Vos et al. describe the findings of a comprehensive au-
topsy study into all cases of unexplained and unexpected
deaths in minors (0–17 years) in the Netherlands over a pe-
riod of 15 months [1]. An interesting finding here is that in
25% of cases no structural abnormalities were found at au-
topsy, which suggests sudden cardiac death (SCD) caused
by an inherited arrhythmogenic disorder. Vos et al. and oth-
ers stress the importance of a systematic autopsy for SCD in
minors and argue that cardiogenetic screening, a ‘molecular
autopsy’, should be performed when the autopsy does not
reveal a structural abnormality which explains the cause of
death [2, 3]. What are arguments for and against molecular
autopsy after SCD in minors?
Multiple studies have revealed a genetic predisposition
to sudden death and that risk for SCD is increased with
a family history of SCD [4–8]. Furthermore, a cardiogenetic
disorder is found in approximately 50% of families of SCD
victims [9–12]. Therefore, systematic autopsy with an op-
tional molecular autopsy after sudden death in minors could
lead to the identification of family members at risk for SCD.
Pooled results of systematic molecular autopsies can also
help to identify markers that improve the accuracy of SCD
risk prediction models, which will likely improve SCD pre-
vention strategies when more families with inheritable ar-
rhythmogenic disorders are identified. The prevalences of
arrhythmogenic disorders are currently thought to be under-
estimated, due to incomplete penetrance, the lack of clinical
phenotype of these disorders, and incomplete family screen-
ing. Increased cardiogenetic screening, not only by molec-
ular autopsy, will bring the estimated prevalences closer to
their actual values. Currently only ~40% of family members
are screened; from a public health viewpoint, this should be
 B. van Driel
b.vandriel@vumc.nl
1 Department of Physiology, VU University Medical Center,
Amsterdam, The Netherlands
2 Department of Cardiology, Erasmus Medical Center,
Rotterdam, The Netherlands
100% so that SCD may be prevented in those at high risk
[13].
However, ethical, legal and financial problems emerge
with attempts to increase genetic screening. Genetic coun-
selling by a clinical geneticist is essential to guide family
members in the decision-making process towards genetic
screening. People have a right not to know, and fear or an-
ticipatory stress play a role in the choice to be screened.
Legally speaking, medical confidentiality should be main-
tained but should be balanced against informing the rela-
tives and respecting their right to be informed. From a fi-
nancial point of view, payment for genetic testing is an issue
because medical insurance stops after death. Furthermore,
carrying a disease-causing mutation can hinder the possi-
bility of obtaining life insurance higher than 268,000 C.
Considering this, the road to systematic molecular autopsy
after SCD in minors is long and winding.
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